Dominik Schneidawind

5PUBLICATIONS
14CO-AUTHORS
Haematological tumoursHumoural immunology and immunochemistryApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 17, 2024
Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib.

Jacqueline Fischer, Estelle Erkner, Pia Radszuweit

|May 23, 2024
B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma.

Kevin D Hofer, Nathan Wolfensberger, Adrian Bachofner

|Feb 08, 2024
Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID-19 prevention.

Julia Trepl, Chloé Pasin, Dominik Schneidawind

|Jan 31, 2024
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.

Emmanuelle Moraes Ribeiro, Kathy-Ann Secker, Ana-Maria Nitulescu

|May 05, 2017
Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.

Corina Schneidawind, Silke Duerr-Stoerzer, Christoph Faul

Pageof 1